Formulation and Evaluation of Solid Lipid Nanoparticles for controlled delivery of Zidovudine

Abstract

Zidovudine is one of the chief nucleoside analogue and reverse inhibitor licensed for HIV infection which is placed along with a group of retroviruses. The present research study on Zidovudine solid dosage form surveyed the feasibility utilizing solid lipid nanoparticles (SLNs) for controlled drug delivery of zidovudine embracing glyceryl behenate as lipidic material, tween 80 as a stabilizer and blend of sodium chelate with poloxamer as surfactant. The SLNs were prepared utilizing high pressure homogenization followed by ultrasonication method. The prepared SLNs were characterized by particle size analysis, polydispersity index, zeta potential, DSC, TEM, IR spectroscopy, and X-ray diffractometry. Narrow size distribution of the particles was marked having polydispersity index values under 0.8. The high zeta potential of the different SLN formulations additionally showed their physical stability. Differential scanning calorimetry and powder X-ray diffraction showed decline in crystallinity of drug in the nanoparticle formulation. In vitro release study showed sustained release for up to 12 hours in the SLN formulations prepared. The current study results revealed that zidovudine SLN formulation prepared by high pressure homogenization followed by ultrasonication is a suitable method for controlled drug delivery system.